Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Lipegfilgrastim"'
Autor:
Ahmed Rashed, Orla M Fitzpatrick, David J Easty, Zac Coyne, Dearbhaile Collins, Victoria Mallet, Maciej Milewski, Keith Egan, Oscar S Breathnach, Liam Grogan, Bryan T Hennessy, Patrick G Morris
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Purpose Breast cancer is one of the most prevalent malignant diseases in women. The development of dose dense chemotherapy regimens has improved clinical outcomes but has been associated with increased hematological toxicity. Currently there
Externí odkaz:
https://doaj.org/article/4387ad9c450c447893806b3be04b7468
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Lipegfilgrastim is a long-acting glycopegylated granulocyte-colony stimulating factor (G-CSF) approved for the management of chemotherapy-induced neutropenia. In general, there is little information on the use of any G-CSFs specifically in patients w
Externí odkaz:
https://doaj.org/article/706d26d29aaa4d3a932f285cad41ef4c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 65-68 (2016)
The main treatment for metastatic soft tissue sarcomas is chemotherapy (CT); neutropenia is its frequent complication that is treated with various colony stimulating factors (CSFs). The purpose of the study was to assess the treatment effectiveness a
Externí odkaz:
https://doaj.org/article/7d11e1cbfd8c432083ec70940c092186
Publikováno v:
Biologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 1-8 (2016)
Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basil
Externí odkaz:
https://doaj.org/article/1d9aa841d64a4175b0b8db2aa414a927
Autor:
G. D. Petrova, T. Z. Chernyavskaya, N. V. Gorbunova, V. N. Kostrykina, V. A. Doronin, K. N. Melkova
Publikováno v:
Онкогематология, Vol 10, Iss 4, Pp 38-43 (2015)
The development of dose-limiting toxicities, including myelotoxicity, can significantly limit cytostatic therapy of malignant tumors. Neutropenia associated with high risk of febrile neutropenia (FN) and infectious complications that may interfere wi
Externí odkaz:
https://doaj.org/article/71e9d31ed12b4593922d9aaa749acb8e
Publikováno v:
Онкогематология, Vol 10, Iss 2, Pp 37-45 (2015)
Neutropenia and associated infection, resulting in hospitalization and use of antibiotics, has a negative effect on chemotherapy. The need to reduce the dose of cytotoxic drugs during neutropenia leads to lower survival rates in patients with hematol
Externí odkaz:
https://doaj.org/article/e6309fd445814f1f87d68647a6043428
Autor:
Hila Magen, Avichai Shimoni, Noga Shem-Tov, Arnon Nagler, Nira Varda-Bloom, Ronit Yerushalmi, Rina Sareli, Ivetta Danylesko
Publikováno v:
International Journal of Hematology. 114:363-372
Autologous stem cell transplantation (ASCT) is a standard of care in newly-diagnosed multiple myeloma (MM) patients. Several studies before the introduction of novel therapies in MM, demonstrated a pegylated G-CSF to be successful in mobilizing perip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b77ec9c42a2ab69f2893e54a32932b82
https://doi.org/10.1007/s12185-021-03177-9
https://doi.org/10.1007/s12185-021-03177-9
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Background: Lipegfilgrastim (Lonquex®) has demonstrated to be non-inferior to pegfilgrastim (Neulasta®) in reducing the duration of severe neutropenia (SN) in patients with stage II−IV breast cancer. Compared to pegfilgrastim, lipegfilgrastim als
Externí odkaz:
https://doaj.org/article/80601741eb7d45b98aaf78628a434212
Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars
Autor:
Gianluca Tomasello, Erika Rijavec, Alice Indini, Fausto Petrelli, Olga Nigro, Michele Ghidini, Simona Polito
Publikováno v:
Expert Opinion on Pharmacotherapy. 22:857-865
Introduction: Severe neutropenia and infections are potentially life-threatening complications of cytotoxic antineoplastic therapies and often require hospitalization with a severe economic impact....
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f62204d897f0bf94d6bb750c2f6bfe7
https://doi.org/10.1080/14656566.2021.1873950
https://doi.org/10.1080/14656566.2021.1873950